Nanjing Zenshine Pharmaceuticals Co. Ltd. has disclosed fused heterocyclic compounds acting as phosphatidylinositol 3-kinase α (PI3Kα) (H1047R mutant) inhibitors reported to be useful for the treatment of cancer.